Hexabrix (ioxaglate), a new low osmolality contrast agent for lumbar epidural double-catheter venography.
Hexabrix (ioxaglate), a new low osmolality contrast agent, has been compared with Télébrix (ioxitalamate) in a series of 50 lumbar epidural venograms. The intensity of the pain and heat sensation experienced by the patient was significantly lower following the injection of Hexabrix. For this reason Hexabrix may be considered the contrast medium of choice for epidural venography. In 15 additional cases Hexabrix was compared with Amipaque (metrizamide) in the same iodine concentration (320 mg/ml). In these patients hardly any difference in pain and heat sensation was observed after the injection of both contrast agents. Frequently only a slight feeling of warmth was noticed. A minimal sensation of pain was occasionally observed to the same degree with both contrast agents.
D002986:Clinical Trials as Topic; D003287:Contrast Media / Q000009:adverse effects; D004824:Epidural Space / Q000098:blood supply; D006801:Humans; D007084:Iliac Vein / Q000000981:diagnostic imaging; D007405:Intervertebral Disc Displacement / Q000000981:diagnostic imaging; D007463:Iodobenzoates / Q000009:adverse effects*; D007483:Iothalamic Acid / Q000009:adverse effects / Q000031:analogs & derivatives*; D007485:Ioxaglic Acid; D009325:Nausea / Q000209:etiology; D010146:Pain / Q000209:etiology; D010292:Paresthesia / Q000209:etiology; D010690:Phlebography / Q000379:methods*; D013115:Spinal Canal / Q000098:blood supply; D014283:Triiodobenzoic Acids / Q000009:adverse effects*
D003287:Contrast Media; D007463:Iodobenzoates; D014283:Triiodobenzoic Acids; D007483:Iothalamic Acid; C002587:ioxitalamic acid; D007485:Ioxaglic Acid